Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.com

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) was upgraded by equities research analysts at StockNews.com to a "sell" rating in a research report issued to clients and investors on Monday.

CRBP has been the subject of a number of other research reports. Wedbush restated an "outperform" rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. Mizuho restated an "outperform" rating and issued a $74.00 target price on shares of Corbus Pharmaceuticals in a report on Friday, September 20th. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, September 23rd. Piper Sandler began coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They set an "overweight" rating and a $35.00 price objective for the company. Finally, B. Riley dropped their target price on Corbus Pharmaceuticals from $85.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $62.00.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ CRBP traded down $0.49 during midday trading on Monday, hitting $11.30. 127,088 shares of the stock traded hands, compared to its average volume of 169,955. Corbus Pharmaceuticals has a one year low of $5.67 and a one year high of $61.90. The business has a 50 day moving average price of $15.26 and a two-hundred day moving average price of $32.72. The company has a market cap of $137.62 million, a PE ratio of -2.41 and a beta of 2.63.

Institutional Trading of Corbus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new stake in shares of Corbus Pharmaceuticals during the 2nd quarter valued at $1,368,000. Rhumbline Advisers purchased a new stake in Corbus Pharmaceuticals during the second quarter worth about $638,000. Victory Capital Management Inc. bought a new stake in Corbus Pharmaceuticals in the second quarter worth about $862,000. Acadian Asset Management LLC bought a new stake in Corbus Pharmaceuticals in the second quarter worth about $716,000. Finally, HighVista Strategies LLC purchased a new position in Corbus Pharmaceuticals in the second quarter valued at about $1,755,000. 64.64% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.